Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

Harmony Biosciences (Nasdaq: HRMY) will present a poster on its ongoing HBS-301 Phase 3 trials at European Narcolepsy Days on October 2–3, 2026.

Rhea-AI Summary

Harmony Biosciences (Nasdaq: HRMY) will present a poster on its ongoing HBS-301 Phase 3 trials at European Narcolepsy Days on October 2–3, 2026. The meeting takes place in Bern, Switzerland, with poster presentations scheduled for October 2 at 16:30 and October 3 at 12:30, both CEST.

The poster covers ONSTRIDE-1 in adults with narcolepsy and ONSTRIDE-2 in adults with idiopathic hypersomnia. Both studies are randomized, double-blind and placebo-controlled. HBS-301 is an investigational formulation of enteric-coated pitolisant being developed to treat excessive daytime sleepiness and other symptoms.

Key Terms

phase 3, idiopathic hypersomnia, double-blind, placebo-controlled, +1 more

5 terms

phase 3 medical

"ongoing Phase 3 trials of HBS-301"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

idiopathic hypersomnia medical

"ONSTRIDE-2 in idiopathic hypersomnia"

A chronic sleep disorder that causes extreme daytime sleepiness and prolonged, unrefreshing sleep despite adequate night sleep, with no identifiable medical or neurological cause. Think of it like a phone battery that won’t hold charge: sufferers remain tired and less productive even after long rest. For investors, idiopathic hypersomnia matters because it creates demand for treatments, diagnostics and supportive services, influencing market opportunities and regulatory pathways in sleep medicine.

double-blind medical

"randomized, double-blind, placebo-controlled studies"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"double-blind, placebo-controlled studies of HBS-301"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

enteric-coated medical

"high-dose formulation of enteric-coated pitolisant tablets"

A coating on a tablet or capsule designed to resist dissolving in the acidic environment of the stomach and instead dissolve when it reaches the higher-pH environment of the small intestine. The coating is usually a pH-sensitive polymer that prevents drug release in the stomach to protect the active ingredient from acid, or to protect the stomach from irritating drugs; its effectiveness depends on gastric pH and transit time, so it is not suitable for medicines that must act immediately or be absorbed in the stomach.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland.

Poster details are listed below:

Abstract Title:	Phase 3, randomized, double-blind, placebo-controlled studies of HBS-301 for narcolepsy and idiopathic hypersomnia
Date/Times:	October 2, 16:30 (CEST) October 3, 12:30 (CEST)

About HBS-301 
HBS-301 is an investigational, optimized, high-dose formulation of enteric-coated pitolisant tablets. HBS-301 is being developed in multiple tablet strengths up to 60 mg to treat excessive daytime sleepiness and other symptoms in patients with narcolepsy or idiopathic hypersomnia (IH). HBS-301 is currently being evaluated in two phase 3 clinical trials. The ONSTRIDE-1 study in adult patients with narcolepsy and the ONSTRIDE-2 study in adult patients with IH. 

About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com